- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00781456
A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy of DR-105 Compared to Placebo For the Management of Menstrually-Related Migraine Headaches.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
California
-
La Mesa, California, Förenta staterna, 91942
- Teva Investigational Site
-
San Diego, California, Förenta staterna, 92108
- Duramed Investigational Site
-
San Diego, California, Förenta staterna, 92123
- Teva Investigational Site
-
San Francisco, California, Förenta staterna, 94109-4841
- Duramed Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, Förenta staterna, 20036
- Duramed Investigational Site
-
-
Florida
-
West Palm Beach, Florida, Förenta staterna, 33409
- Duramed Investigational Site
-
-
Georgia
-
Savannah, Georgia, Förenta staterna, 31406
- Teva Investigational Site
-
-
New Jersey
-
Edison, New Jersey, Förenta staterna, 08817
- Duramed Investigational Site
-
-
New York
-
New York, New York, Förenta staterna, 10022
- Duramed Investigational Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Förenta staterna, 27103
- Teva Investigational Site
-
-
Oklahoma
-
Tulsa, Oklahoma, Förenta staterna, 74105
- Teva Investigational Site
-
-
Oregon
-
Medford, Oregon, Förenta staterna, 97504
- Teva Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19114
- Duramed Investigational Site
-
Uniontown, Pennsylvania, Förenta staterna, 15401
- Teva Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, Förenta staterna, 29201
- Teva Investigational Site
-
Hilton Head, South Carolina, Förenta staterna, 29926
- Teva Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, Förenta staterna, 38120
- Teva Investigational Site
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75234
- Duramed Investigational Site
-
Houston, Texas, Förenta staterna, 77054
- Teva Investigational Site
-
San Antonio, Texas, Förenta staterna, 78258
- Duramed Investigational Site
-
-
Virginia
-
Virginia Beach, Virginia, Förenta staterna, 23454
- Duramed Investigational Site
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Duramed Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Premenopausal, non-pregnant, non-lactating
- History of migraine headaches without aura for at least 6 months
- History of migraine headaches associated with menstruation
- Others as directed by FDA-approved protocol
Exclusion Criteria:
- History of migraine headaches with aura or focal neurological symptoms
- Any contraindication to the use of oral contraceptives
- Others as dictated by FDA-approved protocol
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 91-day Levonorgestrel Oral Contraceptive
Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy, for a total of 13 weeks.
|
91 dagars behandling bestående av 84 blå kombinationstabletter innehållande 150 µg LNG/30 µg EE och 7 gula tabletter innehållande 10 µg EE.
Andra namn:
|
Placebo-jämförare: Placebo
Participants received placebo, 12 weeks (84 consecutive days) of inactive tablets, followed by an additional 7 days of inactive tablets, for a total of 13 weeks.
|
1 tablet daily to match experimental arm
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period
Tidsram: Baseline (25-35 days before Day 1) and Days 1-91
|
The number of participants with at least 50% reduction in migraine frequency (average weekly number of migraine episodes) through the end of the 91-day treatment period compared with Baseline (the 25- to 35-day baseline qualification period).
Participants recorded the incidence, timing and intensity of migraines in a migraine diary during the prequalification period and throughout the 91-day treatment period.
|
Baseline (25-35 days before Day 1) and Days 1-91
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the First, Second and Third Months
Tidsram: Baseline, Month1, Month 2 and Month 3
|
The percentage of participants with at least 50% reduction in migraine frequency (average weekly number of migraine episodes) compared to Baseline at each month of the treatment period.
|
Baseline, Month1, Month 2 and Month 3
|
Change From Baseline in Average Migraine Severity
Tidsram: Baseline and Month 1, Month 2 and Month 3
|
Migraine severity was recorded by participants in the Baseline qualification diary and study migraine diary during the treatment period. Participants could report a severity of none (score = 0), mild (1), moderate (2), or severe (3). In general, if a headache was mild, daily activities could be resumed and little to no medication was taken. Moderate headaches required medication and effected daily activities. Severe headaches were debilitating and required medication. Average migraine severity is defined as the sum of the severity ratings divided by the total number of migraine episodes reported during the observation period (for example, Baseline, First Month, Second Month, Third Month, and 91-Day Treatment Period). A negative change from Baseline score indicates improvement in severity. |
Baseline and Month 1, Month 2 and Month 3
|
Percentage of Participants Who Required Rescue Medications During the Study Period
Tidsram: Baseline, Month 1, Month 2 and Month 3
|
Participants recorded use of rescue medications for migraines in the migraine diary during the course of study treatment.
|
Baseline, Month 1, Month 2 and Month 3
|
Change From Baseline in Migraine Disability Assessment
Tidsram: Baseline and Week 15
|
The migraine disability assessment (MIDAS) test is used to determine how severely migraines affect a patient's life. Participants were asked five questions about how often their headaches limited their ability to go to work or school, to do household work or to do family or leisure activities in the past 3 months. The MIDAS score equals the sum of the days answered for each question and ranges from 0 (no disability) to approximately 270 (severe disability; the upper bound is dependent on the number of days a participant would plan to work or participate in other activities). The MIDAS score is classified into four grades of severity:
|
Baseline and Week 15
|
Change From Baseline in Headache Impact Test
Tidsram: Baseline and Week 15
|
The Headache Impact Test (HIT) is a tool used to measure the impact headaches have on patients' ability to function on the job, at school, at home and in social situations. HIT-6 consists of 6 questions each scored on a scale from Never (6 points) to Always (13 points). The total score ranges from 36 to 78 with higher scores indicating greater impact on life. There was an error in administration of the HIT-6 in this study. Question 6 was not administered, and question 3 from the MIDAS was included instead. Therefore, the total score of the HIT-6 could not be calculated. |
Baseline and Week 15
|
Number of Participants With Adverse Events (AEs)
Tidsram: Up to 15 weeks
|
An AE is any untoward medical occurrence in a clinical investigation participant and which does not necessarily have to have a causal relationship with this treatment or clinical study. The following definitions were used to assess AE severity: Mild: Awareness of signs or symptoms, but they are easily tolerated; Moderate: Enough discomfort to cause interference with usual activity; Severe: Incapacitating, with inability to perform usual activity. Relationship to study drug was assessed as either: None: Causal relationship can be ruled out; Possibly: Causal relationship at least reasonably possible, i.e. relationship cannot be ruled out; Definitely: Causal relationship is certain. A serious adverse event (SAE) is one that met any one of the following criteria:
|
Up to 15 weeks
|
Mean Number of Days of Bleeding or Spotting
Tidsram: 91-day treatment period
|
Bleeding and spotting were recorded by participants in the migraine diary during the 91-day treatment period.
|
91-day treatment period
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Smärta
- Neurologiska manifestationer
- Huvudvärk, primär
- Huvudvärk
- Migränstörningar
- Huvudvärk
- Läkemedels fysiologiska effekter
- Preventivmedel, hormonella
- Reproduktionskontrollmedel
- Preventivmedel, kvinnor
- Preventivmedel, orala, syntetiska
- Levonorgestrel
- Preventivmedel
- Preventivmedel, Oral
Andra studie-ID-nummer
- DR-105-201
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på 91-dagars Levonorgestrel oralt preventivmedel
-
Duramed ResearchAvslutad
-
Teva Women's HealthAvslutadOralt preventivmedel | HemostasFörenta staterna, Italien
-
BayerAvslutadPreventivmedel | Preventivmedel, PostcoitalMexiko
-
Population CouncilAvslutadKvinnlig preventivmedelChile, Dominikanska republiken
-
Health DecisionsEunice Kennedy Shriver National Institute of Child Health and Human Development...AvslutadAnvändning av preventivmedelFörenta staterna
-
BayerAvslutadPreventivmedelSverige, Finland, Ungern, Norge, Storbritannien
-
FHI 360Avslutad
-
Gaziosmanpasa Research and Education HospitalAvslutadBäckensmärta | Isthmocele | Postmenstruella fläckblödningarKalkon
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)AvslutadHIV-infektioner | TuberkulosFörenta staterna, Sydafrika, Malawi, Brasilien, Kenya, Thailand, Botswana
-
BayerAvslutadPreventivmedelBelgien, Sverige, Österrike, Finland, Nederländerna, Tyskland, Danmark, Norge